Advertisement

Macular pigment in ophthalmic practice; a survey

  • Ian J. Murray
  • Batul Hassanali
  • David Carden
Basic Science

Abstract

Background

Macular pigment (MP) might provide some protection against age-related eye disease, and it is now being measured in ophthalmic practice. The purpose of the survey described here was to determine the distribution of MP in a random population of patients in a typical UK ophthalmic practice.

Methods

Macular pigment optical density (MPOD) was measured in 56 patients aged 11 to 87 years, mean 52 ± 19, over a 3-month period. Typically, the test requires setting flicker thresholds for a centrally and peripherally viewed blue/green alternating target. Here we describe the results when an age-based estimate of the peripheral value is used, thus avoiding the peripheral setting. In 32 observers, a comparison was made between this and values obtained with the centre and periphery method. Information on smoking habits, iris colour, diabetic status, and ethnicity were recorded.

Results

The overall average MPOD for the population obtained with the centre-only approach for 56 individuals was 0.400 ± 0.165. The centre-only technique was an accurate predictor of values based on centre and peripheral measures, with 95 % limits of agreement of 0.137 OD units. Pearson’s correlation coefficient showed a high correlation between right and left eyes (r = 0.7 (p < 0.001)). There was a small difference between males and females that did not reach statistical significance (r = −0.22). There was a non-statistically significant age-related decline in MPOD in this particular population (r = −0.17). Dark irides were significantly associated with high MPOD (r = 0.28, p < 0.05). MPOD in Type II diabetic patients was 27 % lower than that in non-diabetics (r = 0.29, p < 0.05).

Conclusion

The technique provides similar values of MP optical density to previous reports. As with other HFP-based methods, in a small percentage of older patients, more than one measurement is required before satisfactory results are obtained.

Keywords

Macular pigment Patient survey Ethnicity Diabetes 

Notes

Acknowledgment

We thank Teresa Tee for helping in the preparation of this paper

References

  1. 1.
    de Jong PT (2006) Age-related macular degeneration. N Engl J Med 355:1474–1485PubMedCrossRefGoogle Scholar
  2. 2.
    Snodderly DM, Brown PK, Delori FC, Auran JD (1984) The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci 25:660–673PubMedGoogle Scholar
  3. 3.
    Leung IY (2008) Macular pigment: new clinical methods of detection and the role of carotenoids in age-related macular degeneration. Optometry 79:266–272PubMedCrossRefGoogle Scholar
  4. 4.
    Hammond BRJ, Wooten BR, Snodderly DM (1997) Individual variations in the spatial profile of human macular pigment. J Opt Soc Am A Opt Image Sci Vis 14:1187–1196PubMedCrossRefGoogle Scholar
  5. 5.
    van der Veen RL, Berendschot TT, Makridaki M, Hendrikse F, Carden D, Murray IJ (2009) Correspondence between retinal reflectometry and a flicker-based technique in the measurement of macular pigment spatial profiles. J Biomed Opt 14:064046PubMedCrossRefGoogle Scholar
  6. 6.
    Khachik F, Bernstein PS, Garland DL (1997) Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 38:1802–1811PubMedGoogle Scholar
  7. 7.
    Landrum JT, Bone RA, Kilburn MD (1997) The macular pigment: a possible role in protection from age-related macular degeneration. Adv Pharmacol 38:537–556PubMedCrossRefGoogle Scholar
  8. 8.
    Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME (2001) Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 42:439–446PubMedGoogle Scholar
  9. 9.
    Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293PubMedCrossRefGoogle Scholar
  10. 10.
    Beatty S, Boulton M, Henson D, Koh HH, Murray IJ (1999) Macular pigment and age related macular degeneration. Br J Ophthalmol 83:867–877PubMedCrossRefGoogle Scholar
  11. 11.
    Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115–134PubMedCrossRefGoogle Scholar
  12. 12.
    Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE (2001) Macular pigment in donor eyes with and without AMD: a case–control study. Invest Ophthalmol Vis Sci 42:235–240PubMedGoogle Scholar
  13. 13.
    Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH (2007) Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 335:755PubMedCrossRefGoogle Scholar
  14. 14.
    Bone RA, Landrum JT, Guerra LH, Ruiz CA (2003) Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 133:992–998PubMedGoogle Scholar
  15. 15.
    Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J (2004) Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75:216–230PubMedCrossRefGoogle Scholar
  16. 16.
    Koh HH, Murray IJ, Nolan D, Carden D, Feather J, Beatty S (2004) Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp Eye Res 79:21–27PubMedCrossRefGoogle Scholar
  17. 17.
    Richer SP, Stiles W, Graham-Hoffman K, Levin M, Ruskin D, Wrobel J, Park DW, Thomas C (2011) Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. Optometry 82:667 e6–680 e6CrossRefGoogle Scholar
  18. 18.
    Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhofer G, Schmidt-Erfurth U, Schmetterer L (2011) Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 52:8174–8178PubMedCrossRefGoogle Scholar
  19. 19.
    Berendschot TTJM, Makridaki M, van der Veen RL, Rob LP, Parry NRA, Carden D, Murray IJ (2011) The clear (combination (of) lutein effects (on) aging retina) study; lutein supplementation improves visual acuity and night vision in early Amd; a two-centre, placebo-controlled study. Invest Ophthalmol Vis Sci 52:E-Abstract 3631Google Scholar
  20. 20.
    Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry NR, Berendschot TT (2013) Lutein supplementation over a 1 year period in early AMD might have a mild beneficial effect on visual acuity; the CLEAR study. Invest Ophthalmol Vis Sci 54(3):1781–1788. doi: 10.1167/iovs.12-10715 PubMedCrossRefGoogle Scholar
  21. 21.
    Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC (2006) Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90:75–80PubMedCrossRefGoogle Scholar
  22. 22.
    Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B (2011) Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 118:2203–2211PubMedCrossRefGoogle Scholar
  23. 23.
    Nolan JM, Feeney J, Kenny RA, Cronin H, O'Regan C, Savva GM, Loughman J, Finucane C, Connolly E, Meagher K, Beatty S (2012) Education is positively associated with macular pigment: the Irish Longitudinal Study on Ageing (TILDA). Invest Ophthalmol Vis Sci 53:7855–7861PubMedCrossRefGoogle Scholar
  24. 24.
    Werner JS, Donnelly SK, Kliegl R (1987) Aging and human macular pigment density. Appended with translations from the work of Max Schultze and Ewald Hering. Vis Res 27:257–268PubMedCrossRefGoogle Scholar
  25. 25.
    Makridaki M, Carden D, Murray IJ (2009) Macular pigment measurement in clinics: controlling the effect of the ageing media. Ophthalmic Physiol Opt 29:338–344PubMedCrossRefGoogle Scholar
  26. 26.
    van der Veen RL, Berendschot TT, Hendrikse F, Carden D, Makridaki M, Murray IJ (2009) A new desktop instrument for measuring macular pigment optical density based on a novel technique for setting flicker thresholds. Ophthalmic Physiol Opt 29:127–137PubMedCrossRefGoogle Scholar
  27. 27.
    Snodderly DM, Mares JA, Wooten BR, Oxton L, Gruber M, Ficek T (2004) Macular pigment measurement by heterochromatic flicker photometry in older subjects: the carotenoids and age-related eye disease study. Invest Ophthalmol Vis Sci 45:531–538PubMedCrossRefGoogle Scholar
  28. 28.
    Xu J, Pokorny J, Smith VC (1997) Optical density of the human lens. J Opt Soc Am A Opt Image Sci Vis 14:953–960PubMedCrossRefGoogle Scholar
  29. 29.
    Nolan JM, Stack J, O' Donovan O, Loane E, Beatty S (2007) Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp Eye Res 84:61–74PubMedCrossRefGoogle Scholar
  30. 30.
    Hammond BR Jr, Wooten BR, Snodderly DM (1996) Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vis Res 36:3003–3009PubMedCrossRefGoogle Scholar
  31. 31.
    Howells O, Eperjesi F, Bartlett H (2011) Measuring macular pigment optical density in vivo: a review of techniques. Graefes Arch Clin Exp Ophthalmol 249:315–347PubMedCrossRefGoogle Scholar
  32. 32.
    Hammond BR Jr, Fuld K, Snodderly DM (1996) Iris color and macular pigment optical density. Exp Eye Res 62:293–297PubMedCrossRefGoogle Scholar
  33. 33.
    Wolf-Schnurrbusch UE, Roosli N, Weyermann E, Heldner MR, Hohne K, Wolf S (2007) Ethnic differences in macular pigment density and distribution. Invest Ophthalmol Vis Sci 48:3783–3787PubMedCrossRefGoogle Scholar
  34. 34.
    Mellerio J, Ahmadi-Lari S, van Kuijk F, Pauleikhoff D, Bird A, Marshall J (2002) A portable instrument for measuring macular pigment with central fixation. Curr Eye Res 25:37–47PubMedCrossRefGoogle Scholar
  35. 35.
    Klein R, Klein BE, Linton KL, DeMets DL (1993) The Beaver Dam eye study: the relation of age-related maculopathy to smoking. Am J Epidemiol 137:190–200PubMedGoogle Scholar
  36. 36.
    Lima VC, Rosen RB, Maia M, Prata TS, Dorairaj S, Farah ME, Sallum J (2010) Macular pigment optical density measured by dual-wavelength autofluorescence imaging in diabetic and nondiabetic patients: a comparative study. Invest Ophthalmol Vis Sci 51:5840–5845PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Faculty of Life SciencesUniversity of ManchesterManchesterUK

Personalised recommendations